For Device Companies, Are FDA Headaches Ahead?
Executive Summary
Guidant Corp.'s failure to get an approval recommendation on July 10 from the FDA's Circulatory Systems Device panel for its Contak CD/Easytrak system to treat congestive heart failure certainly wasn't bad news for other players in cardiac rhythm management (CRM). But for those companies that don't compete directly with Guidant in CRM--and perhaps even for those that do--the push-back by the FDA panel raised some eyebrows. It's entirely possible that the Guidant device simply didn't measure up--that the panel was correct in judging that it didn't meet the clinical end-points required to recommend approval. But some device industry executives worry about the future direction of the FDA's approval process.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 26 March
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 26 March
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
FDA Delivers OTC Monograph Facility Fees For Fiscal 2024 With Highlights On Some RSVPs
FDA “is highlighting” in its FY2024 facility fees announcement, and using italics for “emphasis added” for some statements, that businesses previously but no longer making hand sanitizers, though still selling the products, should contact the agency to assure they’re not assessed fees.